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Genetic Monitoring in the Workplace:
A Tool Not a Solution*
Lillian Trettin, Catherine Musham & Richard Jablonski**
Introduction
Health risks endured by workers as a result of exposure to toxic
substances is a recurring theme in the story of American industry.
Occupational medicine, the discipline arising from the need to protect
the health and safety of workers, seeks to identify potential risks in
workplace environments and implement appropriate interventions.
Genetic testing may be used to predict health and has considerable
promise for industrial risk assessment. However, due to public
opposition to the sweeping use of predictive health tests, its pros and
cons continue to be debated. For instance, a recent article in Newsweek
warns: "Flunk the Gene Test and Lose Your Insurance."1 Much of
this attention stems from public interest in the Human Genome
Project, one of the first international biological initiatives of the 1990's
to result in radically new medical technology.
Increasingly, conferences have been convened to discuss the
Genome Project and the multitude of ethical, social, and legal issues
surrounding the use of genetic testing. As organizers of one such
conference asked in 1995, "[w]hat is the appropriate balance between
encouraging biotechnological innovation while protecting the public
from risks that accompany any new technology?" 2
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1 Greg Cowley, Flunk the Gene Test and Lose Your Insurance, Newsweek,
December 23, 1996.
2 Gianna Julian-Arnold & Suzanne Sprunger, Promoting and Managing Genome
Innovation, 7 Risk 197 (1996).
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This article will examine the potential risks and benefits of a new
type of predictive testing: genetic monitoring based on advances in
biomarker research. The future development of this technology is
particularly applicable to hazardous workplaces, where the incentive to
test employees for exposure to toxicants has been substantial. As these
tests improve, it will become feasible to determine whether a worker
was exposed to toxicants and whether the exposure results in increased
risk for particular diseases, including some forms of cancer.
The key issue is whether genetic monitoring can offer significant
benefits to occupational medicine (and society in general) without the
discrimination and confidentiality violations that have plagued genetic
screening. Theoretical support for examining a new medical technology
in terms of its social implications and consequences is provided by((social constructionism." This perspective emphasizes the importance of
considering medical or technological issues in the full social context of
scientific and lay knowledge and practices. Rather than question the
effectiveness of technological advances, it aims to understand and
interpret their potential impact through cultural and social analysis. 3
Following an explanation of the differences in screening and
monitoring and a brief history of each procedure, this paper discusses
potentially greater benefits of monitoring along with the problems that
could result from its use. Next, the paper points out that that
investigation of the ethical, social and legal aspects of genetic
monitoring in urgently needed to ensure that it will be used
constructively is occupational medicine and not as an instrument of
discrimination. Several specific issues that require further study are
identified. Finally, we conclude that genetic monitoring has a
significant role to play in occupational medicine, but it does not offer
an easy solution to the many social problems that have accompanied use
of genetic screening.
Genetic Screening and Monitoring Defined
Although not obvious in popular semantic usage, the definitions of
screening and monitoring are precise and distinctive according to
3 See Deborah Lupton, Medicine as Culture: Illness, Disease and the Body in
\Vestern Societies (1994).
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biomedical and occupational medicine literature. Much of the writing
in this area discusses the relative advantages of genetic screening and
monitoring using these definitions as a basis for comparison. 4
Genetic screening focuses on the individual. It is defined as a one-
time-only test that determines if an individual possesses inherited traits
that increase his or her risk of a specific disease. Typically, this approach
is used to measure the likelihood that an individual will develop a
particular disease, prior to the appearance of symptoms. Although
screening criteria is based on populations at risk, the application of this
procedure is focused on the individual rather than the population.
Validity and reliability are of key importance in screening procedures.
Genetic monitoring, on the other hand, focuses on the environment.
It uses a form of medical surveillance to identify hazards in the
environment before they cause disease. John Last writes that the
purpose of monitoring is: "to detect changes in the trend to distribution
in order to initiate investigative or control measures." 5 Thus, the
emphasis is on the population, not the individual, and the ultimate
purpose is to reduce risk by changing the environment. Accuracy of
individual test results is less important than in the case of screening.
Historical Perspectives
Based on government and corporate reports, news accounts, and
interviews with corporate and government officials, scientists, and labor
experts, many scholars conclude that applications of genetic screening
in the workplace show a history of discrimination. 6 For instance,
susceptibility to toxic chemicals has been falsely linked to genetic
conditions associated with particular ethnic groups, making it appear
that there are "scientific reasons" for discrimination against them.7
Discrimination against African Americans at risk of developing sickle-
cell anemia, a genetically inherited condition which has nothing to do
with exposure to toxic chemicals, is a glaring example. Gender has also
4 See Nicholas A. Ashford et al., Monitoring the Worker for Exposure and
Disease: Scientific, Legal, and Ethical Considerations in the Use of Biomarkers
(1990); Americans With Disabilities Act 42 U.S.C. §§ 12101-12213 (1990).
5 John M. Last, Dictionary of Epidemiology (1993).
6 See Dorothy Nelkin & Laurence Tancredi, Dangerous Diagnostics: The Social
Power of Biological Information (1989); Elaine Draper, High Risk Workers or High
Risk Work, 6 Int'I. J. Sociology & Soc. Pol'y 12 (1986).
7 Id.
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been a basis for discrimination, as exemplified by the corporate trend in
"fetal exclusion policies" of the 1970's and 1980's. Non-sterile women
of childbearing age were regularly restricted from holding certain
hazardous (but lucrative) jobs to avoid the possibility of lawsuits from
genetic damage to fetuses through exposure should they be
"irresponsible" enough to become pregnant.8
Recently, the genetic makeup of individual workers or groups of
workers has become a focus of occupational disease in much the same
way "worker carelessness" was a focus of industrial safety programs at
the turn of the century. Prior to the recent advent of regulatory
controls, genetic screening gave the appearance of providing a "scientific
basis" on which to exclude workers presumed to have health risks from
employment. In addition to genetic screening, many industries
routinely monitor for emissions. Both are less costly alternatives than
high-priced engineering solutions.
Because of these and other cases, workplace screening to ensure
employee health and safety is out of favor with legislators, regulators
and many business leaders. Public concern over confidentiality of test
data and potential discrimination by employers and insurers
culminated in congressional hearings and a ruling in 1995 that people
with genetic abnormalities are covered under the Americans with
Disabilities Act (ADA). 9 In the interest of better assuring
confidentiality, federal officials proposed a more comprehensive law in
1997 to "protect the privacy of medical records, to let consumers
inspect their own files and to punish any unauthorized disclosures of
personal data by hospitals, insurers, health plans or drug companies." 10
Genetic monitoring is regarded enthusiastically by many as a
revolutionary new way to protect workers from exposure-linked disease.
They predict immense benefits. Potential application in the work place
is the driving force behind much of the research in genetic monitoring.
The use of biological markers in occupational medicine is not new.
What is new is the increased sensitivity of the current generation of
8 Id.
9 See Elaine Draper, Social Issues of Genome Innovation and Intellectual
Propert, 7 Risk 201 (1996); Americans With Disabilities Act 42 U.S.C. % 12101-
12213 (1990).
10 Richard Pear, Clinton to Back a Law on Patient Privacy, N. Y. Times, Aug. 10,
1997 at A4.
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biomarkers. Scientists' ability to work with biomarkers at the molecular
level has increased dramatically since the 1960's and 1970's, when
corporations like Dow Chemical initiated monitoring programs. In
1982, pioneering molecular epidemiologist Frederica Perera and her
colleagues noted that a well-known class of carcinogens, resulting from
exposure to tobacco smoke, polluted household air, or barbecue-grilled
foods as well as workplace pollutants, left a unique "fingerprint" in
human lung and blood cells - an adduct (a complex that results when
a chemical attaches to a biological molecule, usually to DNA or a
protein in a cell). Subsequent studies showed that people with higher
levels of these adducts had heightened likelihood of developing various
cancers.1 1 Increasingly, biologists claim, these biomarkers will make it
possible to flag critical precancerous events within the body long before
clinical evidence is available.
Recent advances in biomarkers make it possible to identify an exact
continuum of events in the progressive development of a disease like
cancer. Biomarkers are generally classified into three groups: biomarkers
of exposure, effect, or susceptibility. An exposure marker indicates
increased levels of a specific toxicant in the body. An effect marker
exhibits temporary or permanent response to that exposure, such as cell
mutation. A susceptibility marker measures an individual's innate
(genetic) or acquired capacity for responding to an exposure. 12 There
is some debate over what kind of markers are the most useful. Markers
of susceptibility offer the greatest possible benefit of early detection,
but their reliability is questionable and subject to conflicting
interpretations. Genetic monitoring generally focuses on markers of
exposure and effect.
Currently, biomarker technology is not sophisticated enough for
precise and uniformly dependable test results. Given these limitations,
reliable early detection of disease is not always possible. 13 However, it
is likely that with further development, biomarker technology can be
used to monitor any population at risk for exposure to harmful
11 See Frederica P. Perera, Uncovering New Clues to Cancer Risks, Scientific
American, May 1996 at 54.
12 See Rogene E. Henderson & Jonathan B. Ward, Identification of Needs in
Biomarker Research, 104 Envtl. Health Perspectives 895 (1996).
13 See Perera, supra note 11 and Ashford et al., supra note 4.
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environmental toxicants, to determine whether they have been exposed
to a particular toxicant, and, if so, whether they have sustained
reversible or irreversible damage. Scientists predict that it will soon be
feasible to identify a set of markers in an individual and assess the
likelihood that the person will acquire, or will be at heightened risk of
acquiring cancer. At this time the number of dependable monitoring
programs (for example, monitoring for the work-related chronic
beryllium disease), is limited. 14
The enthusiasm about biological monitoring should be balanced
with understanding of the potential social effects, including possible
abuses of this technology. Workplace monitoring programs will have to
deal with the existing context of policy decisions brought about by
industry's experience with genetic screening. The potential for
enhanced preventive interventions in the hazardous workplace using
monitoring procedures is striking. However, many of the ethical, social,
legal and economic issues raised by screening apply to monitoring as
well. Genetic monitoring is likely to create some social problems.
For example, in 1977 after monitoring employees for over ten
years, Dow Chemical's company scientists found evidence that workers
exposed to benzene and epichlorohydrin showed high rates of
chromosome breakage. Proponents hailed the research for identifying
the industry's hazardous risks. However, opponents criticized the
research as unreliable and charged that publicizing it would induce
unwarranted stress in workers before real impacts could be
determined. 15 Debates of this kind over the results of monitoring are
likely to occur in the future and may affect its prospects.
Discussion
Proponents claim that biological monitoring will result in overall
health improvements and will support a mandate to change the
hazardous workplace rather than change the worker.16 This claim
14 See Perera, supra note 11; see F. Joseph Furman et al., Rocky Flats Beryllium
Health Surveillance, 104 Env'1 Health Perspectives 981 (1996).
15 See Elaine Draper, Risky Business: Genetic Testing and Exclusionary Practices in
the Hazardous Workplace (1991).
16 See Paul A. Schulte, Introduction: The Role of Biomarkers in the Prevention of
Occupational Disease, in Biomarkers and Occupational Health: Progress and
Perspectives 1 (Mortimer Mendelsohn et al. eds., 1995).
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requires close examination. Unfortunately, historical evidence shows
that workers exposed to health hazards ranging from unsafe settings to
toxic substances have been blamed for careless behavior, failure to use
correct procedures or good judgment, and - more recently -
perceived health risk on the job. It is still the case that corporate
findings more often target problematic individuals or groups than more
expensive engineering problems involved in changing workplace
environments. It is possible that eventually genetic monitoring will be
used in this capacity rather than its intended purpose.
Some scholars ask: why not reduce the potential for health threat to
the lowest possible denominator based on the findings of monitoring
and thereby avoid unforeseen dangers to all workers rather than gather
evidence that certain workers are likely to develop health problems and
assume that, if those workers are eliminated, the workplace is "safe"? 17
In simplest terms, these scholars raise a basic social-constructionist
dilemma, shaped by partisan interests: workers would like to make the
workplace as hazard-free as possible. Employers want to protect their
workforce, but prefer means that minimize legal and financial liability
- most often, a policy of removing problem workers. Resolving this
dilemma is not simple.
Pragmatists question whether it is realistic to resolve the dilema by
insisting on zero-risk conditions in the workplace, given current market
conditions. From that perspective, there may be little practical
alternative to removing high-risk employees from the most hazardous
workplaces if our society continues to support demands for products
that require the use of hazardous substances for which we identify no
replacements. A potential solution to the problem of displaced high-risk
workers would be for companies to offer them a "worker removal
policy" that guarantees them salaries and benefits comparable to those
they previously earned. Under the Occupational Safety & Health
Administration (OSHA), lead and benzene are now regulated in this
way. Some economists like W.K. Viscusi believe that these expensive
financial reimbursement practices will eventually force employers to
provide safer workplaces. 18 However, the obvious limitation is that
17 See Draper, supra note 15.
18 See Ashford et al., supra note 4 and W. Kip Viscusi, Risky Business, 12 J.
Policy Anal. & Mgmt. 399 (1993).
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worker removal or rotation programs only divert attention from the
primary prevention measure of cleaning up a dangerous workplace.
Meanwhile, even harsh critics of workplace testing indicate that, as
it becomes more precise, biomarker-based monitoring has the potential
to better serve workers' interests than genetic screening because of the
potential for arresting or avoiding disease in the most vulnerable. 19
Whether employers will adopt monitoring programs based on this
without mandates remains to be seen. Monitoring programs could
prove costly and legally threatening for companies. Employers,
corporate physicians and third-party payers have all demonstrated their
preference for one-time-only procedures like screening. One time only
procedures facilitate sorting workers into high-risk and low-risk groups,
cost less than repeated monitoring, and provide "scientifically
objective" data.2 0 However, if monitoring acquires the weight of
regulatory mandate or otherwise gains widespread support it will be
truly beneficial only if workers can avoid being segregated into "high
risk" and "low risk" groups and can maintain a sense of control over the
data collected. 2 1 This will remain difficult to achieve. Those most
likely to face the prospects of biomarker-based monitoring in the future
readily identify and express vital interest in these concerns.
The Need For Research on Related Ethical and Social Issues
Ethical questions are of pressing concern, as are questions of
economic cost and benefit.22 Concerns persist about the reliability and
cost effectiveness of monitoring programs and about the use of
information derived from such programs. Specific issues that should be
studied include: the increased impact of new systems of information
management on employees' privacy and autonomy, tacit cultural
assumptions about the role of monitoring and data management in
occupational medicine, and the input of people who are likely to be
affected by the use of genetic information in the workplace.
19 See Draper, supra note 15.
20 See Nelkin & Tancredi, supra note 6; Draper, supra note 15; Draper, supra
note 9, and Neil A. Holtzman, Medical and Ethical Issues in Genetic Screening: An
Academic View, 104 Envt'l Health Perspectives 987 (1996).
21 See Draper supra note 15; Draper, supra note 9.
22 See Holtzman, supra note 20.
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Innovations in managing research data have been fueled by the
Human Genome Project. Charles Cantor writes that tremendous
changes in data management are needed. He predicts that specialized
data banks concerned with only a part of the genome and requiring
sophisticated information linkages will be developed. 2 3 Resulting
improvements in "informatics" - computerized information
management systems - have aided rapid access to genome data and
promoted development of large-scale programs of biological research in
academia and industry.24 This should affect monitoring programs.
Privacy and discrimination are crucial issues for all medical,
especially genetic, data. Greeley concludes that statistical data
management may ultimately more affect health management than the
most dramatic medical innovations from human genome research.
Unlike medical prediction geared toward the individual, statistical
prediction sorts groups (like employees or job applicants) into positions
of high and low potential medical costs.2 5 The danger increases that
discrimination will be based on assessment of an individual's record, or
on that individual's statistical association with an undesirable group.
The potential for statistical evaluation of "trends" in health risk is
particularly strong for monitoring. Research must determine what
safeguards can be designed to protect monitored data from misuse.
Further research is also needed on tacit cultural assumptions about
biomedical research in contemporary Western societies. Scholars have
made numerous claims about underlying beliefs. The growth of
medical technology and associated research dollars is said to artificially
elevate the role of diagnostic testing in health care. The result is that
some people adopt or are labeled with a "potential sick" role based on
the prevalence of testing.26
A proposed metaphor comparing the body to a computer implies
that modern societies think of disease as an "information malfunction"
23 See Charles Cantor, The Challenges to Technology and Informatics, in The
Code of Codes: Scientific and Social Issues in the Human Genome Project 98 (Daniel
J. Kevles & Leroy Hood eds., 1992).
24 See 7 Human Genome News 3, at 4 (1995).
25 See Horace T. Greely, Health Insurance, Employment Discrimination, and the
Genetics Revolution, in The Code of Codes: Scientific and Social Issues in the
Human Genome Project 264 (Daniel J. Kevles & Leroy Hood eds., 1992).
26 See Lupton, supra note 3.
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that more data can correct. This metaphor is in contrast to growing
recognition that some chronic illnesses are not "curable" as were earlier
major diseases like smallpox, cholera and polio. 27 Applying biological
assumptions in non-clinical settings may lead to blaming the individual
for his or her own poor health (or perceived risk of it) due to "bad
genes" or a weak immune system. This makes it easier to redefine
socially derived problems as individuals' problems, thereby reducing
public accountability and protecting routine institutional practices.2 8
These concerns are as relevant to monitoring as to screening - perhaps
more so, if the illusion that advanced technology and more data
necessarily promote better health grows stronger.
Such underlying beliefs have readily discernible political and social
dimensions. As anthropologist Emily Martin wrote, a healthy immune
body, resistant to disease, becomes a new form of "cultural capital" in
Western society. Issues of preventive intervention quickly become
partisan: If a politically strong majority requires preventive intervention,
the costs seem legitimate and reasonable. If a weak minority requires
intervention (e.g, those with AIDS) then the working, healthy immune
system predominates and costs for the immunity-impaired might well
be considered wasteful. 2 9 The result can be a "caste" of the potentially
weak or seemingly disease-prone. Workers in one plant, during the
early days of implementing OSIA standards, identified such a group
as a "leper colony".3 0
A strategy for conducting research on tacit cultural assumptions as
they apply to monitoring programs could combine close analysis of
descriptions of the workplace from a variety of sources (e.g., news
media, popular literature, corporate correspondence, worker interviews)
with reader responses to hypothetical texts in a study with controlled
experimental design.3 1
27 See Lupton, supra note 3; Edward S. Golub, The Limits of Medicine: How
Science Is Reshaping Our Search for the Cure (1994).
28 See Nelkin, supra note 6.
29 See Emily Martin, Flexible Bodies: Tracking Immunity in American Culture
(1994).
30 Sheldon W. Samuels, A Moral History of the Evolution of a Caste of Workers,
104 Envd Health Perspectives 918 (1996).
31 See Martin, supra note 29; Peter M. Sandman et al., Agency Communication,
Community Outrage, and Perception of Risk: Three Simulation Experiments, 13
RiskAnal. 585 (1993).
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Research should also examine expressed opinions of non-specialists,
such as front-line workers, who will eventually face the prospect of
workplace monitoring. In 1997, as part of a pilot project, five focus
groups were conducted in two midsize industrial cities in the Southeast
with a range of potential stakeholders. Using a fictional but plausible
scenario to generate discussion, researchers interviewed human resource
managers, company physicians and nurses, third-party payers,
attorneys, and front-line workers (both unionized and non-unionized)
to learn how their perspectives on monitoring varied. 32 Initial results of
this study indicate that at least some members of all these groups share
concerns over the reliability of monitoring and question how practical it
would be to use it in today's workplace.
Participants in this study agreed that biological monitoring has
potentially constructive uses but that it is likely to result in employee
discrimination, given the United States' current social structure and
values. All groups saw inevitable conflict between industry's interests
and employees' well-being. Managers doubted that companies would
adopt monitoring due to increased liabilities and cost. Workers
(particularly non-unionized workers) were highly concerned about who
would control monitored data and whether increased preventive
benefits would offset the risk of job discrimination or loss of health
insurance coverage. They questioned whether the need for baseline data
as a basis for comparing monitored data would reopen the door to
screening. All participants in this study agreed on the importance of
measures to ensure employees of protection from discriminatory uses of
biological monitoring. Despite its limited scale, the results of this
research are instructive and indicate the need for additional qualitative
research and surveys of the potential social consequences of monitoring,
particularly in light of what is already known about screening in the
workplace. This research would extend the argument for a socially
constructed policy by further examining the ordinary workplace
context in which groups of relevant stakeholders form opinions about
biological monitoring.
32 See Catherine Musham et al., Biomarker-based Health Monitoring in the
Work place: Perspectives of Diverse Stakeholder Groups. A Focus Group Study,
unpu lished manuscript, Environmental Hazards Assessment Program, Medical
University SC (1997).
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Research of this kind, aimed at clarifying the social dimensions of
medical policy, maintains that ethical decisions about medical
technology will have practical application only if they are embedded in
an understanding of real-world situations. 33 Preliminary research with
stakeholder groups strengthens the recognition that stakeholders need
forums in which to air their concerns and resolve their differences
before innovative monitoring programs can have a chance of
succeeding. 34 To date, experts and scholars have written extensively
about possible applications of biological testing in industry and related
social, legal, and ethical issues. However, there has been little
investigation of the perspectives of "non-experts" who are likely to be
involved in and affected by biomarker-based decision-making. 35
For instance, Draper's important treatment of genetic testing as a
"social construct" considers only the insights of top authorities and
policy makers. It does not consider input from the wide range of
business executives, attorneys, third-party payers, and health care
professionals who will likely be involved with and affected by biological
monitoring in the future. 3 6 Nor does Draper interview any of
America's front-line workers, the group most likely to be affected
personally by this testing and most frequently identified in the
literature as potential victims of its misuse. Studies are needed that
record insights of people like these based on their day-to-day workplace
experience.
Efforts to draw public attention to innovations in biological
monitoring may ignite controversy. Although not as dramatic as
"cloning," biomarker research is more likely to impress people with its
immediate uses and consequences. Industrial leaders, front-line
workers, occupational health professionals, environmental attorneys and
third-party payers are likely to be affected by potential uses of
biological monitoring. It will be important to bring these diverse
stakeholder groups together to obtain their practical insights into
33 See Barry Hoffmaster, Morality and the Social Sciences, Social Science, in
Perspectives on Medical Ethics 241 (George Weisz, ed., 1990).
34 Rogene E. Henderson & Jonathan B. Ward, Identification of Needs in
Biomarker Research, 104 Envtl. Health Perspectives 895 (1996).
35 William Freudenburg, Risky Business, 99 Am. J. Soc. 835 (1993) (book review).
36 See Draper supra, note 15.
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biological monitoring while awareness of biomarker research is still
limited. The process of identifying similarities and differences in
stakeholder perspectives may avert eventual conflict by suggesting areas
of agreement and areas requiring negotiation. Research on health
promotion innovations emphasizes the importance of taking this
step. 37 Otherwise, biomarker-based monitoring will have no more
success than screening in occupational medicine.
Conclusion
Although monitoring has advantages compared with screening, a
great deal of research needs to be done to ensure that it will be used in a
socially constructive manner. Nothing will stop the rapid advance of
genetic research. Given the inevitability of tremendous gains in
knowledge about the human genome, the need for understanding of
the social impact of its potential applications is critical. Monitoring uses
of genetic information in the workplace raises a host of ethical, social
and legal issues that should be studied and fully understood before this
technology becomes widely available. Issues of confidentiality,
ownership and storage of genetic information collected through
monitoring procedures are as pressing and complex as those pertaining
to that obtained through screening procedures. It is generally agreed
that decisions regarding the use and regulation of genetic monitoring
are needed to safeguard its benefits for occupational medicine and
minimize the possibility it will be used for discriminatory purposes.
A social constructionist approach suggests that the extent to which
polices are based upon a balanced decision-making process, one that
acknowledges and equitably reflects views of varied and competing
interest groups will lagely determine whether genetic monitoring can be
as socially beneficial as proponents claim. Genetic monitoring has great
promise in occupational medicine with obvious advantages over genetic
screening. However, given the range of social and ethical issues related
to its potential uses, it is not a simple solution.
37 See Mario A. Orlandi, The Diffusion and Adoption of Worksite Health
Promotion Innovations: An Analysis of Barriers, 15 Preventive Med. 522 (1996).
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